Speaker illustration

Doctor Filipa Gerardo

Hospital Professor Doutor Fernando Fonseca, Amadora (Portugal)

Unveiling the eligibility for screening of cardiac amyloidosis in a real world population

Event: Heart Failure 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Valvular heart disease 4

Thumbnail

Single centre 3-year experience in intermittent levosimendan infusion

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: ePosters in chronic heart failure - pharmacotherapy 5

Thumbnail

Unlocking stability: predictors of clinical stability in patients undergoing intermittent levosimendan infusions for advanced heart failure

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: ePosters in acute heart failure 12

Thumbnail

Patiromer in hyperkalemia management: real-world perspective for spironolactone-untreated patients

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: ePosters in acute heart failure 8

Thumbnail

Predicting hospitalizations through post-discharge heart failure appointment: evaluating the FENNIX score's performance

Event: Heart Failure 2024

Topic: Biomarkers

Session: Acute heart failure - diagnostic methods 2

Thumbnail

Risk of bleeding in patients with atrial fibrillation: ARC-HBR outperforms HASBLED

Event: Heart Failure 2024

Topic: Epidemiology, Prognosis, Outcome

Session: ePosters in arrhythmias and device therapy 1

Thumbnail

Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease

Thumbnail

Eligibility for acetazolamide in real-world acute heart failure patients

Event: Heart Failure 2023

Topic: Treatment

Session: Chronic heart failure - treatment 5

Thumbnail

Unveiling the Unsusual: A rare case of transient cardiomyopathy in a young male

Event: Heart Failure 2023

Topic: Myocardial Disease

Session: Myocardial disease 3

Thumbnail

Cystatin C is better than creatine for prognostic evaluation in heart failure patients

Event: Heart Failure 2023

Topic: Epidemiology, Prognosis, Outcome

Session: ePosters in chronic heart failure - epidemiology, prognosis, outcome 2

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb